Imatinib Mesylate — A New Oral Targeted Therapy
Publication type: Journal Article
Publication date: 2002-02-28
scimago Q1
wos Q1
SJR: 19.076
CiteScore: 96.4
Impact factor: 78.5
ISSN: 00284793, 15334406
PubMed ID:
11870247
General Medicine
Abstract
This review discusses the development and uses of imatinib mesylate, a protein tyrosine kinase inhibitor useful in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors that was recently approved by the Food and Drug Administration. Imatinib targets platelet-derived growth factor receptor, inhibits the fusion product of the Philadelphia chromosome, and targets c-kit, a protein tyrosine kinase. The drug may also be effective in the treatment of other tumors that express platelet-derived growth factor receptor or c-kit.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
2
4
6
8
10
12
14
16
18
|
|
|
Blood
17 publications, 2.62%
|
|
|
Leukemia and Lymphoma
11 publications, 1.69%
|
|
|
Journal of Clinical Oncology
10 publications, 1.54%
|
|
|
PLoS ONE
6 publications, 0.92%
|
|
|
Annals of Oncology
5 publications, 0.77%
|
|
|
Gastroentérologie Clinique et Biologique
5 publications, 0.77%
|
|
|
Leukemia Research
5 publications, 0.77%
|
|
|
Therapeutic Drug Monitoring
5 publications, 0.77%
|
|
|
Cancers
5 publications, 0.77%
|
|
|
Cancer Genetics and Cytogenetics
5 publications, 0.77%
|
|
|
Cancer
5 publications, 0.77%
|
|
|
Molecular Cancer Therapeutics
5 publications, 0.77%
|
|
|
Journal of Molecular Diagnostics
4 publications, 0.62%
|
|
|
Oncotarget
4 publications, 0.62%
|
|
|
International Journal of Molecular Sciences
4 publications, 0.62%
|
|
|
International Journal of Hematology
4 publications, 0.62%
|
|
|
Oncogene
4 publications, 0.62%
|
|
|
British Journal of Haematology
4 publications, 0.62%
|
|
|
American Journal of Hematology
4 publications, 0.62%
|
|
|
Recent Results in Cancer Research
4 publications, 0.62%
|
|
|
European Journal of Cancer
3 publications, 0.46%
|
|
|
Acta Haematologica
3 publications, 0.46%
|
|
|
New England Journal of Medicine
3 publications, 0.46%
|
|
|
Nature Communications
3 publications, 0.46%
|
|
|
Annals of Hematology
3 publications, 0.46%
|
|
|
Leukemia
3 publications, 0.46%
|
|
|
Cancer Chemotherapy and Pharmacology
3 publications, 0.46%
|
|
|
BMC Cancer
3 publications, 0.46%
|
|
|
Cancer Letters
3 publications, 0.46%
|
|
|
2
4
6
8
10
12
14
16
18
|
Publishers
|
20
40
60
80
100
120
140
|
|
|
Elsevier
140 publications, 21.57%
|
|
|
Springer Nature
118 publications, 18.18%
|
|
|
Wiley
83 publications, 12.79%
|
|
|
Taylor & Francis
46 publications, 7.09%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
32 publications, 4.93%
|
|
|
MDPI
17 publications, 2.62%
|
|
|
American Society of Hematology
17 publications, 2.62%
|
|
|
SAGE
12 publications, 1.85%
|
|
|
American Chemical Society (ACS)
11 publications, 1.69%
|
|
|
American Association for Cancer Research (AACR)
11 publications, 1.69%
|
|
|
American Society of Clinical Oncology (ASCO)
11 publications, 1.69%
|
|
|
Oxford University Press
9 publications, 1.39%
|
|
|
S. Karger AG
8 publications, 1.23%
|
|
|
Frontiers Media S.A.
7 publications, 1.08%
|
|
|
Public Library of Science (PLoS)
6 publications, 0.92%
|
|
|
Spandidos Publications
5 publications, 0.77%
|
|
|
Impact Journals
4 publications, 0.62%
|
|
|
Cold Spring Harbor Laboratory
4 publications, 0.62%
|
|
|
Mary Ann Liebert
3 publications, 0.46%
|
|
|
Massachusetts Medical Society
3 publications, 0.46%
|
|
|
BMJ
3 publications, 0.46%
|
|
|
Georg Thieme Verlag KG
3 publications, 0.46%
|
|
|
American Society for Clinical Investigation
2 publications, 0.31%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
2 publications, 0.31%
|
|
|
Baishideng Publishing Group
2 publications, 0.31%
|
|
|
Journal of Neurosurgery Publishing Group (JNSPG)
2 publications, 0.31%
|
|
|
Springer New York
2 publications, 0.31%
|
|
|
The Korean Society of Hematology
2 publications, 0.31%
|
|
|
Society for Translational Oncology
2 publications, 0.31%
|
|
|
20
40
60
80
100
120
140
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
649
Total citations:
649
Citations from 2025:
18
(2.77%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Savage D. Imatinib Mesylate — A New Oral Targeted Therapy // New England Journal of Medicine. 2002. Vol. 346. No. 9. pp. 683-693.
GOST all authors (up to 50)
Copy
Savage D. Imatinib Mesylate — A New Oral Targeted Therapy // New England Journal of Medicine. 2002. Vol. 346. No. 9. pp. 683-693.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1056/NEJMra013339
UR - https://doi.org/10.1056/NEJMra013339
TI - Imatinib Mesylate — A New Oral Targeted Therapy
T2 - New England Journal of Medicine
AU - Savage, David
PY - 2002
DA - 2002/02/28
PB - Massachusetts Medical Society
SP - 683-693
IS - 9
VL - 346
PMID - 11870247
SN - 0028-4793
SN - 1533-4406
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2002_Savage,
author = {David Savage},
title = {Imatinib Mesylate — A New Oral Targeted Therapy},
journal = {New England Journal of Medicine},
year = {2002},
volume = {346},
publisher = {Massachusetts Medical Society},
month = {feb},
url = {https://doi.org/10.1056/NEJMra013339},
number = {9},
pages = {683--693},
doi = {10.1056/NEJMra013339}
}
Cite this
MLA
Copy
Savage, David. “Imatinib Mesylate — A New Oral Targeted Therapy.” New England Journal of Medicine, vol. 346, no. 9, Feb. 2002, pp. 683-693. https://doi.org/10.1056/NEJMra013339.
Profiles